Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 16, 1998, Pages 2235-2240

  Buckman, Brad O ^a   Mohan, Raju ^a   Koovakkat, Sunil ^a   Liang, Amy ^a   Trinh, Lan ^a   Morrissey, Michael M ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,7 DIHYDRO[4,5 B][1,4]OXAZINE 6 ONE; 7,8 DIHYDROPTERIDINE 6(5H) ONE; AMIDINOARYLOXY 9 BENZYL 8 METHYL 9H PURINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SPECIFICITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICOAGULANTS; BINDING SITES; CATTLE; DRUG DESIGN; FACTOR XA; HUMANS; INDICATORS AND REAGENTS; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; TRYPSIN INHIBITORS;

EID: 0032544159     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00386-2     Document Type: Article

References (19)

1. 1. Mann, K. G.; Nesheim, M. E.; Church, W. R.; Haley, P.; Krishnaswamy, S. Blood 1990, 76, 1.
2. 2. (a) Shaw, K. J.; Guilford W. J.; Dallas, J. L.; Koovakaat, S. K.; Liang, A.; Light, D. R.; Morrissey, M. M. J. Med. Chem. in press
3. th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-201.
4. th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-121.
5. 3. (a) Phillips, G. B.; Buckman, B. O.; Davey, D. D.; Eagen, K. A.; Guilford, W. J.; Hinchman, J.; Ho, E.; Koovakkat, S.; Liang, A.; Light, D. R.; Mohan, R.; Ng, H. P.; Post, J.; Smith, D.; Subramanyam, , B.; Sullivan, M. E.; Trinh, L.; Vergona, R.; Walthers, J.; White, K.; Whitlow, M.; Wu, S.; Xu, W.; Morrissey, M. M. J. Med. Chem., in press.
6. th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-122
7. th ACS National Meeting, Dallas, March 29-April 2 (1988), MEDI-123
8. th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-124
9. th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-125.
10. th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-126.
11. 5. Trost, B. M.; Curran, D. P. Tetrahedron Lett. 1981, 14, 1287.
12. 6. Okada, K.; Tanino, H.; Hashizume, K.; Mizuno, M.; Kakoi, H.; Inoue, S.; Blount, J. F. Tetrahedron Lett. 1988, 39, 4403.
13. 6) δ 9.10 (br s, 2), 8.80, br s, 2), 7.70 (m, 2), 7.50 (dd, 1), 7.40-7.20 (m, 4), 7.10 (d, 1), 4.90 (s, 2), 3.00 (s, 3), 2.90 (s, 3).
14. 6) δ 9.10 (br s, 2), 8.80 (br s, 2), 7.70 (d, 1), 7.65 (d, 1), 7.50 (dd, 1), 7.40-7.25 (m, 8), 7.10 (d, 1), 5.40 (s, 2), 3.00 (s, 3), 2.90 (s, 3), 2.70 (s, 3).
15. 9. Morrison, J. F. Biochem. Biophys. Acta 1969, 185, 269.
16. 10. The models were constructed using the program Cerius2 version 2.3 from Molecular Simulations, Inc. The models of the FXa binding of structures 22 were built based on the X-ray crystal structure of an analog of 5 bound to Trypsin. In constructing the models of 22a and 22b, the two phenoxy rings were held in the same relative position to each other as in the X-ray crystal structure bound to Trypsin.
17. th ACS National meeting, Dallas, March 29-April 2 (1998), MEDI-133.
18. 12. Stubbs, M. T.; Huber, R.; Bode, W. FEBS Lett. 1995, 375, 103.
19. 13. Brandstetter, H.; Kuhne, A.; Bode, W.; Huber, R.; von der Saal, W.; Wirthensohn, K.; Engh, R. A. J. Biol. Chem. 1996, 217, 29988.